CAJ | 학술논문

背景与目的晚期非小细胞肺癌是一种无法治愈的常见恶性肿瘤。对于多程治疗后复发的患者目前尚无标准的治疗方法。本文分析了苹果酸舒尼替尼单药治疗多次复发的晚期非小细胞肺癌的疗效及安全性。方法回顾性分析我科2011年1月-2012年12月采用苹果酸舒尼替尼37.5 mg/d持续给药的方法治疗的17例多程治疗后复发的晚期非小细胞肺癌患者的近期疗效、毒副反应及无进展生存时间。结果17例患者中部分缓解1例（5.9%），稳定7例（41.2%），疾病进展9例（52.9%），客观缓解率5.9%，疾病控制率47.1%，中位无进展生存为4.4个月（95%CI：4.05-7.46）。全组患者治疗耐受良好，3级/4级不良反应仅表现为手足皮肤反应（5.9%），其余药物相关不良事件均为1/2级。结论苹果酸舒尼替尼37.5 mg/d持续治疗多程治疗后复发的晚期非小细胞肺癌可取得较好的客观疗效，耐受良好。
배경여목적만기비소세포폐암시일충무법치유적상견악성종류。대우다정치료후복발적환자목전상무표준적치료방법。본문분석료평과산서니체니단약치료다차복발적만기비소세포폐암적료효급안전성。방법회고성분석아과2011년1월-2012년12월채용평과산서니체니37.5 mg/d지속급약적방법치료적17례다정치료후복발적만기비소세포폐암환자적근기료효、독부반응급무진전생존시간。결과17례환자중부분완해1례（5.9%），은정7례（41.2%），질병진전9례（52.9%），객관완해솔5.9%，질병공제솔47.1%，중위무진전생존위4.4개월（95%CI：4.05-7.46）。전조환자치료내수량호，3급/4급불량반응부표현위수족피부반응（5.9%），기여약물상관불량사건균위1/2급。결론평과산서니체니37.5 mg/d지속치료다정치료후복발적만기비소세포폐암가취득교호적객관료효，내수량호。
Background and objective Advanced non-small cell lung cancer (NSCLC) is a common malignancy that is incurable. No standard treatment exists for recurrent patients. hTis article analyzed the effcacy and safety of sunitinib (37.5 mg qd) on a continuous daily dosing (CDD) schedule in treating recurrent advanced NSCLC. Methods We retrospec-tively analyzed the short-term effcacy and toxicity of sunitinib CDD in treating 17 patients who had previously undergone multiple cycles of therapy for advanced NSCLC in our hospital from January 2011 to December 2012. Treatment-related survival was also analyzed. Results Among the 17 patients, the best overall response was partial response in 1 patient (5.9%), stable disease in 7 patients (41.2%), and progressive disease in 9 patients (52.9%). hTe overall response rate was 5.9%, and the disease control rate was 47.1%. hTe median progression-free survival was 4.4 months (95%CI:4.05-7.46). hTe main grade 3/4 toxicity was hand-foot skin reaction. Conclusion Sunitinib (37.5 mg QD) CDD enabled good objective response in advanced NSCLC patients who had previously received multiple cycles of treatment and was well tolerated.